Search Results for "Merck Serono Geneva Strike Today"
Original Source: Merck Pharmaceuticals
The Merck Group is a global pharmaceutical and chemical company. In 2005, Merck Group sales totaled € 5,870 million. Adjusted for the disposal of VWR in the second quarter of 2004, this represents an increase of 9.9% over 2004. We increased our research and development spending, which has already been substantial for a number of years, by 19% to € 713 million. The operating result rose by a favorable 14% to € 883 million; return on sales (ROS) was 15.0% and return on capital employed (ROCE) reached a...
Matching Channels
Somatropin Hgh rDNA Merck Serono
Interferon beta-1a rDNA Merck Serono
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the...
Matching News
Strike back on cards as Merck Serono talks fail
Staff at Merck Serono's headquarters in Geneva, which has been earmarked for closure, are to vote next Thursday on strike action, after conciliation talks through a Swiss mediation agency failed to r...
Merck Serono staff in Geneva are to hold a half-day strike on 31 July following the breakdown of attempts to reach an agreement with management over the closure of its Swiss headquarters in Switzerla...
Merck Serono spins out bioinformatics newco
The Merck Serono S.A. division of Merck KGaA (Xetra:MRK) launched newco Quartz Bio (Geneva, Switzerland) to provide biomarker data management and exploratory biomarker analysis services. Merck Serono...
Former Merck Serono headquarters in Geneva could host a new Wyss Institute
A dedicated consortium comprised of the École Polytechnique Fédérale de Lausanne (EPFL), the University of Geneva (UNIGE), Dr. Hansjörg Wyss and the Bertarelli family has developed a project to co...
Quintiles offers lifeline to Merck Serono employees
Quintiles has said it will make at least 100 job offers within the next three months to workers set to lose their jobs as a result of the closure of Merck Serono's Geneva headquarters. Earlier this mo...
Merck Serono spins out newco to develop AD assets
The Merck Serono S.A. division of Merck KGaA (Xetra:MRK) launched Asceneuron (Geneva, Switzerland) to develop the division's preclinical Alzheimer's disease programs targeting microtubule-associated p...
[Merck Serono] spins out [Prexton Therapeutics]; provides €2.1mm in seed funding
In the wake of closing the company’s Geneva headquarters and dealing with resulting restructuring, [Merck Serono SA] has spun out some of its preclinical Parkinson’s disease assets into a new comp...
Merck Serono's third Geneva spin-off will take a tilt at Tau
The third spin-off from Merck Serono's soon-to-be closed headquarters in Geneva, Switzerland, has been named as Asceneuron, and will focus on developing small molecule drugs for Alzheimer's disease t...
Matching PubMed Articles
Synthesis of 5-Carboxamide-oxazolines with a Passerini-Zhu/Staudinger-Aza-Wittig Two-Step Protocol.
A new electronic device for subcutaneous injection of IFN β-1a.
Disease-modifying drugs (DMDs) can provide important benefits for patients with multiple sclerosis (MS), but nonadherence to treatment is associated with an increased risk of relapse. All first-line D...
Indole-pyrrolidines were identified as inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) by high-throughput screening. Optimisation of the initial hit through structure-based design l...
New phenoxyacetic acid antagonists of CRTH2 are described. Following the discovery of a hit compound by a focused screening, high protein binding was identified as its main weakness. Optimization aime...
